The Future Vaccine Manufacturing Research Hub (Vax-Hub)

Lead Research Organisation: University College London
Department Name: Biochemical Engineering

Abstract

Vaccines are the most successful public health initiative of the 20th century. They save millions of lives annually, add billions to the global economy and extended life expectancy by an average of 30 years. Even so, the UN estimates that globally 6 million children each year die before their 5th birthday. While vaccines do exist to prevent these deaths, it is limitations in manufacturing capacity, technology, costs and logistics that prevent us for reaching the most vulnerable. The UK is a world leader in vaccine research and has played a significant leadership role in several public health emergencies, most notably the Swine Flu pandemic in 2009 and the recent Ebola outbreak in West Africa. While major investment has been made into early vaccine discovery - this has not been matched in the manufacturing sciences or capacity. Consequently, leading UK scientists are forced to turn overseas to commercialise their products.

Therefore, this investment into The Future Vaccine Manufacturing Hub will enable our vision to make the UK the global centre for vaccine discovery, development and manufacture. We will create a vaccine manufacturing hub that brings together a world-class multidisciplinary team with decades of cumulative experience in all aspects of vaccine design and manufacturing research. This Hub will bring academia, industry and policy makers together to propose radical change in vaccine development and manufacturing technologies, such that the outputs are suitable for Low and Middle Income Countries.
The vaccine manufacturing challenges faced by the industry are to (i) decrease time to market, (ii) guarantee long lasting supply - especially of older, legacy vaccine, (iii) reduce the risk of failure in moving between different vaccine types, scales of manufacture and locations, (iv) mitigating costs and (v) responding to threats and future epidemics or pandemics. This work is further complicated as there is no generic vaccine type or manufacturing approach suitable for all diseases and scenarios. Therefore this manufacturing Hub will research generic tools and technologies that are widely applicable to a range of existing and future vaccines.
The work will focus on two main research themes (A) Tools and Technologies to de-risk scale-up and enable rapid response, and (B) Economic and Operational Tools for uninterrupted, low cost supply of vaccines. The first research theme seeks to create devices that can predict if a vaccine can be scaled-up for commercial manufacture before committing resources for development. It will include funds to study highly efficient purification systems, to drive costs down and use genetic tools to increase vaccine titres. Work in novel thermo-stable formulations will minimise vaccine wastage and ensure that vaccines survive the distribution chain. The second research theme will aim to demystify the economics of vaccine development and distribution and allow the identification of critical cost bottlenecks to drive research priorities. It will also assess the impact of the advances made in the first research theme to ensure that the final cost of the vaccine is suitable for the developing world.

The Hub will be a boon for the UK, as this research into generic tools and technologies will be applicable for medical products intended for the UK and ensure that prices remain accessible for the NHS. It will establish the UK as the international centre for end-to-end vaccine research and manufacture. Additionally, vaccines should be considered a national security priority, as diseases do not respect international boundaries, thus this work into capacity building and rapid response is a significant advantage.

The impact of this Hub will be felt internationally, as the UK reaffirms its leadership in Global Health and works to ensure that the outputs of this Hub reach the most vulnerable, especially children.

Planned Impact

To become an International Centre of Excellence the Hub will interact with multiple stakeholders in the vaccine community and ensures that the benefits of this research are felt far and wide. The immediate beneficiaries of this work will be the organisations who engage with the Hub, including UK industry and academia, Catapults, such as the National Biologics Manufacturing Centre and LMIC vaccine manufacturers. The outputs from this work will also assist other manufacturing Hubs and further the work of the UK Vaccine Network, as many of the research topics tie into strategic policy areas. This work will create new and improved vaccines for LMICs, enable our ability to respond to epidemic scenarios and ultimately boost the UK bio-economy by advancing vaccine manufacturing.

The mechanism of engagement will be through training and online courses, conferences and publications in peer-reviewed journals, feasibility projects that feed projects into the Catapults centres, and Expert Interaction Vouchers. These will be promoted through existing networks such as KTN, academic networks, other Hubs and the Developing Country Vaccine Manufacturing Network (DCVMN).

Training and Online Courses. The Hub members currently run training programmes in bioprocessing, analytics and vaccine development as part of its CPD offering to the vaccine industry and research outputs from the Hub will be included into these training programmes. We will offer funding for 10 places annually for academics and industry from LMICs to attend these courses. To address the national shortage of Qualified Persons (QPs), we will recruit two trainee QPs and provide them with hands-on training in user GMP manufacturing facility, and mentorship to allow them to complete their training and support industry needs. A dedicated Training officer will ensure maximum dissemination of the Hub's work, especially to the DCVMN, by creating online training material that will survive beyond the grant period.
Conferences and Publications. The Hub will hold an all user annual meeting where outputs from the Grand Challenges and Feasibility projects are presented. All partners will be encouraged to publish in Open Access journals. Business Briefings, Special Interest Groups and Industry Open Days, will ensure we continue to increase user engagement over the lifetime of the Hub and create the trained individuals with skills to take the industry forward.
Feasibility Projects will benefit all users that are not currently part of the Hub. Each project can range from a minimum of 6 months to 3 years and receive funding of up to a maximum of £100k p.a. for personnel, PI time and consumables. These grants will explore early technologies and help to generate pilot data for follow on funding. It will link to Catapults, such as the National Biologics Manufacturing Centre, to test feasibility.
Expert Interaction Vouchers will be available for UK and LMIC vaccine manufacturers. Vouchers (up to £35k per voucher) can cover the cost of travel, subsistence and consultancy. It can also be used to fund a maximum 6-month secondment to a facility or research group to build expertise.

LMICs are beneficiaries of this work, which will improve the supply capacity and cost base of existing vaccines and introduce new vaccine technologies to these groups. The vaccine candidates researched by the Hub are on pathogens that primarily affect low-income countries listed on the DAC list, such as malaria, Rift Valley fever, Dengue, pneumococcal disease and TB. Other DAC listed countries will benefit from Hub activities, as we will interact through the DCVMN to offer training, consultancy and secondments through interaction vouchers and feasibility projects.

Organisations

Publications

10 25 50

publication icon
Moisley KM (2019) Optimising proliferation and migration of mesenchymal stem cells using platelet products: A rational approach to bone regeneration. in Journal of orthopaedic research : official publication of the Orthopaedic Research Society

 
Description The Vax-Hub has now established a robust internal and external management structure and staff are progressing with their research outcomes, working on the three technologies. Significant achievements have been obtained for each:
Technology 1: Establishment of a single-use adenovirus manufacturing platform, this has now made GMP compliant and is being used towards manufacture of a vaccine against COVID-19.
Technology 2: Virus-like Particle vaccines production process for Dengue fever, Foot-and-Mouth Disease, Malaria.
Technology 3: Conjugate vaccines - novel strains have been produced and tested, automated microscale methods developed for rapid process development
Processes for Platform Funding have been established, with two calls for £10K interaction vouchers completed and projects announced. Training aims have also been completed, with more than 30 places assigned to LMIC manufacturers employees for courses run worldwide.
Exploitation Route The new technologies and methods developed by the Vax-Hub will be crucial in ensuring vaccine supply at reduced cost:
Technology 1: Establishment of a single-use GMP compliant adenovirus manufacturing platform, this is a flexible platform able to work with multiple serotypes which is easily transferable to LMIC manufacturers with limited capabilities
Technology 2: Virus-like Particle vaccines production process for Dengue fever, Foot-and-Mouth Disease, Malaria. Findings from these projects is in collaboration with companies and aims at translating some of the novel constructs and engineering methodologies to them before end of the grant
Technology 3: Conjugate vaccines - the methods being established aim at a new strain and method capable of producing Pneumococcal vaccine doses at reduced cost.
Sectors Healthcare,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology

 
Description A policy engagement training workshop is being organised targeted at post-doctoral researchers which will provide an overview of the policy-making process including how and when to most effectively engage with policy-makers in order to feed into the policy-making cycle and will enable PDRAs to consider Vax Hub research in light of current vaccine policy challenges in a co-design session with policy makers.
Geographic Reach Multiple continents/international 
Policy Influence Type Influenced training of practitioners or researchers
 
Title Fully integrated automated screening platform 
Description Automation of preculture, cell culture, harvest and periplasmic extraction has all been achieved in one seamless protocol without the need of user interaction from the start to finish. Measurements of cell growth is included and through integrating the robotic platform with MatLab it has been possible to integrate all outputs created within the process to inputs required; for example preculture optical density (extent of growth) is measured and inoculation volumes are calculated using this value. This integration with Matlab and for the whole platform to be handsfree is novel to the institution and a useful tool which can be applied to other projects. This will be published and presented in upcoming events 
Type Of Material Improvements to research infrastructure 
Year Produced 2020 
Provided To Others? No  
Impact This screening tool can be used on any number of cell culture projects and adapted as needed for different protocols. The integration is novel and can be used to instruct other users within and outside the institution. 
 
Title Modeling and optimisation of vaccine supply chains 
Description The focus is on is developing a vaccine supply-chain model that can simulate the flow of vaccine doses from manufacturing plants to service delivery points where vaccines are administered to targeted patients. The model may be used to optimise supply chain operations, ensuring uninterrupted supply of vaccines at minimum cost per dose delivered. The long-term objective is to integrate such supply-chain models with vaccine manufacturing process models in order to capture the interplay between vaccine manufacturing and supply-chain performance. 
Type Of Material Computer model/algorithm 
Year Produced 2020 
Provided To Others? No  
Impact We are developing a case study in a LMIC (Tanzania). The data were collected from websites and contacts with various organisations, including WHO, GAVI, UNICEF and PATH, as well as local governments. The developed vaccine supply chain model is capable of simulating the flow of vaccines from central vaccine store to district vaccine stores (four echelon model). 
 
Title Techno-economic modeling of conjugate vaccine production 
Description The focus is on a conjugate vaccine for pneumonia. Currently used chemical conjugation technology makes this vaccine expensive and a bioconjugation technique is under development by colleagues within the Vax Hub (GC1.1.2). Our research aims at comparing the production processes of pneumonia vaccines using both chemical and biological conjugation in term of techno-economics. 
Type Of Material Computer model/algorithm 
Year Produced 2020 
Provided To Others? No  
Impact We have developed semi-empirical models of the upstream production processes (bioreactors) as well as data-driven models for the downstream separation and purification processes. These models will feed into the commercial simulator SuperPro Designer. Future steps will entail using this platform for identifying hot spots in the production process, optimizing some of the operating conditions and the production schedules, and conducting a techno-economic comparison between chemically and biologically conjugated vaccines. In the long run, these process modeling capability will be integrated with vaccine supply chain modeling to optimize the whole vaccine value chain. 
 
Description Assuring the quality of dengue vaccine in a VLP form 
Organisation National Institute for Biological Standards and Control (NIBSC)
Country United Kingdom 
Sector Public 
PI Contribution In order to assure the quality of dengue vaccine, in a VLP form, a set of robust analytics will be developed. Those analytics methods will allow the characterization and quality evaluation at small scale. There is a lack of robustness in commercially available reference materials/Antibodies; collaboration with an organisation such as NIBSC, who will be working either directly or indirectly with dengue or dengue based materials in various forms, will allow the best commercially available materials to be identified.
Collaborator Contribution NIBSC will provide scientific advice as well as biological materials which will have a major impact on the development of the analytics for the biochemical and immunochemical characterization of the dengue vaccine.
Impact The outputs/outcomes that are aimed to be achieved with this collaboration will have a direct impact on the development of robust analytics for product characterization and quality evaluation,at small scale, as far as the biochemical and immunchemical properties are concerned.
Start Year 2020
 
Description Establishing the use of microscale chromatography-for downstream process optimization of Group B streptococcus polysaccharides 
Organisation MSD Wellcome Trust Hilleman Laboratories
Country India 
Sector Charity/Non Profit 
PI Contribution UCL Biochemical Engineering has extensive experience in using scale-down technologies for the rapid definition of protein purification protocols. This will be applied to development and optimization of assays and protocols for use in manufacture of conjugate vaccines. Once developed at UCL the procedures and assays will be transferred to Hilleman Labs for routine use in process development for this and other vaccines
Collaborator Contribution Hilleman Labs is developing a polysaccharide conjugate vaccine against Group-B Streptococcus (GBS). They will provide access to current materials and methodologies for process development. Assays and protocols developed at UCL will be transferred to Hilleman Labs for routine use in development of future vaccines in a LMIC environment.
Impact Successful VaxHub Interaction voucher application for 6 month pilot project. Value £10,000 Poster abstract submitted for presentation at the ECI Vaccine Technology VIII conference, June 14 -19 2020. Title: Design of a lectin based bacterial polysaccharide assay for high throughput process development of conjugate vaccine products.
Start Year 2019
 
Description Exploiting genetic diversity of Saccharomyces cerevisiae for VLP production 
Organisation Phenotypeca
Country United Kingdom 
Sector Private 
PI Contribution Expertise in the design and development of novel VLP vaccines to investigate the feasibility of the S. cerevisiae expression platform.
Collaborator Contribution Expertise in the use of yeast strains (Saccharomyces) and high-throughput screening for the expression of therapeutic proteins.
Impact Successful application to interaction voucher from Vax-Hub to progress proof of concept studies.
Start Year 2020
 
Description Exploring the potential of solid dose vaccines 
Organisation Enesi Pharma
Country United Kingdom 
Sector Private 
PI Contribution Development of a supply-chain optimisation model including solid dose vaccines in comparison to traditional vaccine doses.
Collaborator Contribution Providing Vax Hub with some technical details about the solid dose properties, including stability.
Impact No impact yet. Disciplines involved: operational research; process systems engineering; vaccine manufacturing
Start Year 2019
 
Description Hilleman Labs 
Organisation MSD Wellcome Trust Hilleman Laboratories
Country India 
Sector Charity/Non Profit 
PI Contribution Intellectual contribution and vaccine development and production.
Collaborator Contribution Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description Hilleman Labs Vax-Hub Partner 
Organisation MSD Wellcome Trust Hilleman Laboratories
Country India 
Sector Charity/Non Profit 
PI Contribution Collaborating Organisation and Partnership under the Future Targeted Healthcare Manufacturing Hub
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, including valuable LMIC perspective.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2020
 
Description Improvment of a Microbial Platform for Dengue Vaccine Production for Low and Medium Income Countries (LMICs) 
Organisation PT Bio Farma
Country Indonesia 
Sector Private 
PI Contribution The platform being developed uses yeast Pichia pastoris, a versatile and potentially cost-effective factory for the production of Virus-Like-Particles (VLP) for four dengue virus serotypes as a vaccine candidate. We are investigating the upstream design space to optimize both quantity and quality of the dengue vaccine prototypes (DENV1-4 vaccine). We will focus our presentation on reporting the optimisation of the upstream processing design space for the production of the serotypes, also we will report on both the quantity and the quality of the desired product, before purification steps. Furthermore, we will share our experience on how international industrial-academic partnership can successfully develop tools and technologies to de-risk scale-up and enable rapid response. So far the main achievements are: 1-Benchmark carried out in situ at Bio Farma 2-Identified-uncertainty regarding the location of VLP (intracellular vs secreted) 3-Improvment of analytics for the biophysical and biochemical properties of the product
Collaborator Contribution PT Bio Farma has hosted me at their site in Indonesia, guided me through a run through of their production process, enabling a full understanding of the entire process (UPS and DSP). During that period, I was also able to benchmark the process. Moreover, they have subsequently sent a pellet of harvested cells from their bioreactor, allowing me to begin troubleshooting and optimizing the vital quality control assays. We anticipate receipt of the stabilized producer cell-line within the next few months, at which point we will begin the process benchmarking and optimization.
Impact The expecting outputs/outcomes will be: 1- Optimization of fermentation operation Optimization of culture medium Optimization of feeding rate and induction regime Integration with initial recovery steps 2- Development of robust analytics for product characterization and quality evaluation at small scale: Biophysical properties: DLS and TEM Biochemical properties: SDS-PAGE, Western Blot, LC MS/MS Immunochemical properties: ELISA (standard and/or Luminex)
Start Year 2019
 
Description Merck MSD 
Organisation Merck
Country Germany 
Sector Private 
PI Contribution Collaboration on vaccine development
Collaborator Contribution Intellectual contribution and vaccine development and production
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description MiniTEM analysis characterisation of VLP, viral vaccines and vectors 
Organisation Vironova
Country Sweden 
Sector Private 
PI Contribution The project will compare images obtained with the standard uracyl acetate based negative stain with those obtained using non-radiactive stains which are more suitable for use within a manufacturing QC environment. Furthermore, it will assess the suitability of MiniTEM system to provide image data of various VLPs and viral vectors to allow for setting of appropriate QC standards. The ability of the Vironova AB automated VIAS analysis software to detect variations from these defined standards as part of a QC environment will be assessed.
Collaborator Contribution Vironova AB will make available a MiniTEM system, a smaller, more compact and simpler version of the powerful analytical tool TEM, based in the Crick Institute (London) for a period of 6 months, where the team at UCL (Stephen Morris and Salome de Sa Magalhaes) will have access to. Moreover, it will provide a glow discharge to be installed at UCL BE facilities for sample preparation as well as initial training, support, sample optimisation and an expert in image analysis to extract data from the images.
Impact Successful voucher application for the period of 6 months starting in April 2020 with an allocated award value of £10K.
Start Year 2020
 
Description PT Bio Farma Vax-Hub Partner 
Organisation PT Bio Farma
Country Indonesia 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Targeted Healthcare Manufacturing Hub
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub including valuable LMIC perspective via participation in Hub meetings,
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Pall Europe Ltd Vax-Hub Partner 
Organisation PALL Europe
Country United Kingdom 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Vaccine Manufacturing Research Hub
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 pa. Other contributions e.g. provision of training and support / Dissemination using database of bioscience companies / Access to proprietary roadmap for software / Sponsorship of networking events valued @£5,000 per year.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Phenotypeca Vax-Hub Partner 
Organisation Phenotypeca
Country United Kingdom 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Targeted Healthcare Manufacturing Hub
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 per year
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Sartorius Stedim Vax-Hub Partner 
Organisation Sartorius
Department Sartorius Stedim Biotech
Country France 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Targeted Healthcare Manufacturing Hub
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued at £1000 pa.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Scaling and Screening Platform for PGCT Technology 
Organisation London School of Hygiene and Tropical Medicine (LSHTM)
Country United Kingdom 
Sector Academic/University 
PI Contribution At UCL we have developed and are working on the scaling of the current bench scale process of bioconjugation within E.coli. We are developing an automated screening platform at the microscale to screen for favourable cell culture conditions before scaling up to larger scales using engineering correlations.
Collaborator Contribution LSHTM is working on biothechnological developments of Protein Glycan Coupling Technology (PGCT) used to produce glycoconjugate vaccines in E. coli cells. The main research activities involve genetic engineering of bacterial strains, and rational design, molecular cloning, and mutagenesis of carrier proteins and glycan components of the glycoconjugate vaccines in development. Functionality of the engineered strains and vaccine production are tested at LSHTM. Selected PGCT strains are then shared with UCL for use in the automated screening platform. Both partners are working to improve and potentially optimise whole process flowsheet development aimed at minimising the steps required for glycoconjugate vaccine production in order to reduce manufacturing costs.
Impact This collaboration is multidisciplinary involving at its core two post-doctoral research fellows; from LSHTM, Marta Mauri, who specialises in the field of molecular biology ad bacteriology; and from UCL, Jasmin Samaras, who has experience in fluid mechanics and biochemical engineering. Outputs will include: -min. two publications of the work being done -a scale down automated platform for the screening of both upstream and downstream processing steps -a method to scale both to smaller and larger volumes
Start Year 2019
 
Description Serum Institute of India 
Organisation Serum Institute of India
Country India 
Sector Private 
PI Contribution We are working with SII staff to understand the reasons why some recombinant yeast isolates produce a higher yield of virus like particle vaccines than others.
Collaborator Contribution SII are providing us with genomic DNA from recombinant yeast as well as advice on optimisation of vlp yield.
Impact The work is still at an early stage with no outputs as yet.
Start Year 2019
 
Description UK Bioindustry Association (BIA) Vax-Hub Partner 
Organisation BioIndustry Association
Country United Kingdom 
Sector Charity/Non Profit 
PI Contribution Collaborating Organisation and Partnership under the Future Targeted Healthcare Manufacturing Hub
Collaborator Contribution Staff time including rovision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 pa.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Univercells Vax-Hub Partner 
Organisation Univercells Ltd
Country Belgium 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Targeted Healthcare Manufacturing Hub
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 pa.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2020
 
Description VABiOTECH Vax-Hub Partner 
Organisation Vietnam Ministry of Health
Department Company for Vaccine and Biological Production No.1
Country Viet Nam 
Sector Public 
PI Contribution Collaborating Organisation and Partnership under the Future Targeted Healthcare Manufacturing Hub
Collaborator Contribution Provision of advice and guidance on the overall direction and progress of the Hub including valuable LMIC perspective via participation in Hub meetings, valued @£1000 per day.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Vabiotech vaccine production 
Organisation VabioTech
Country Viet Nam 
Sector Public 
PI Contribution Intellectual contribution and vaccine development and production.
Collaborator Contribution Intellectual contribution and vaccine development and production.
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description Vaccitech Vax-Hub Partner 
Organisation Vaccitech Ltd
Country United Kingdom 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Targeted Healthcare Manufacturing Hub
Collaborator Contribution Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 pa.
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description Vironova Vax-Hub Partner 
Organisation Vinnova
Country Sweden 
Sector Private 
PI Contribution Collaborating Organisation and Partnership under the Future Targeted Healthcare Manufacturing Hub
Collaborator Contribution use of facilities/equipment e.g. access to manufacturing equipment for validating scale down studies, new and novel technologies and relevant analytical equipment/ Access to QA / Planning data / Database for network building / Analytical equipment / Manufacturing platforms Staff time including provision of advice and guidance on the overall direction and progress of the Hub via participation in Hub meetings, valued @£1000 pa
Impact Working within a network of users and academics to deliver the Hub's vision to make the UK the global centre for integrated discovery through to bioprocess manufacture of next-generation vaccines.
Start Year 2019
 
Description huvepharma 
Organisation Huvepharma
Country Bulgaria 
Sector Private 
PI Contribution Intellectual contribution, vaccine development and production.
Collaborator Contribution Intellectual contribution, vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Impact Intellectual contribution and vaccine development and production. Vaccine technology Vaccine upscaling and manufacture
Start Year 2020
 
Description Economist interview 
Form Of Engagement Activity A press release, press conference or response to a media enquiry/interview
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Public/other audiences
Results and Impact I was interviewed by a journalist from The Economist
Year(s) Of Engagement Activity 2020
URL https://www.economist.com/international/2020/02/06/the-race-to-produce-a-vaccine-for-the-latest-coro...
 
Description May 2019 and November 2019 Vax-Hub Users Group Meetings 
Form Of Engagement Activity A formal working group, expert panel or dialogue
Part Of Official Scheme? No
Geographic Reach International
Primary Audience Industry/Business
Results and Impact These all-day events bring together Vax-Hub researchers and academics and current and prospective industry collaborators. The events feature research updates, industry presentations, a poster session and networking. The purpose of the events is to share knowledge and build new and existing collaborative relationships between industry and academia. As a result, some of those present have since formed collaborations and joined the Hub.
Year(s) Of Engagement Activity 2019
 
Description Viral Vectors for Vaccines and Gene Delivery Workshop 
Form Of Engagement Activity Participation in an activity, workshop or similar
Part Of Official Scheme? No
Geographic Reach National
Primary Audience Industry/Business
Results and Impact This one-day meeting was jointly organised by the Future Vaccine Manufacturing Research Hub (Vax-Hub), the Future Targeted Healthcare Manufacturing (FTHM) Hub and the Knowledge Transfer Network and offered a programme of invited talks, a poster session and an interactive panel discussion. The meeting brought together ~110 participants from industry, academia, government, sector organisations, to inform and discuss the common manufacturing and analytical challenges across the major viral vector products.
Year(s) Of Engagement Activity 2019